NCT01491490View on ClinicalTrials.gov

Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Schizophrenia

Interventions

DRUG

GWP42003 : GWP42004 (40:1)

Capsules taken once a day for 6 weeks

DRUG

Placebo

Capsules taken once a day for 6 weeks

Trial Locations (6)

Unknown

Birmingham

Leicester

Oxford

South London

Surrey

West London

Sponsors

Lead Sponsor

GW Research Ltd

All Listed Sponsors

lead

GW Research Ltd

INDUSTRY

NCT01491490 - Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine | Biotech Hunter | Biotech Hunter